Prosecution Insights
Last updated: April 19, 2026
Application No. 16/239,354

PRESSURE-SENSING INTRAVASCULAR DEVICES, SYSTEMS, AND METHODS

Non-Final OA §103
Filed
Jan 03, 2019
Examiner
CERIONI, DANIEL LEE
Art Unit
3791
Tech Center
3700 — Mechanical Engineering & Manufacturing
Assignee
Volcano Corporation
OA Round
10 (Non-Final)
65%
Grant Probability
Moderate
10-11
OA Rounds
3y 9m
To Grant
93%
With Interview

Examiner Intelligence

Grants 65% of resolved cases
65%
Career Allow Rate
485 granted / 749 resolved
-5.2% vs TC avg
Strong +29% interview lift
Without
With
+28.6%
Interview Lift
resolved cases with interview
Typical timeline
3y 9m
Avg Prosecution
81 currently pending
Career history
830
Total Applications
across all art units

Statute-Specific Performance

§101
9.3%
-30.7% vs TC avg
§103
40.4%
+0.4% vs TC avg
§102
17.5%
-22.5% vs TC avg
§112
30.5%
-9.5% vs TC avg
Black line = Tech Center average estimate • Based on career data from 749 resolved cases

Office Action

§103
DETAILED ACTION Notice of Pre-AIA or AIA Status The present application is being examined under the pre-AIA first to invent provisions. In the event the determination of the status of the application as subject to AIA 35 U.S.C. 102 and 103 (or as subject to pre-AIA 35 U.S.C. 102 and 103) is incorrect, any correction of the statutory basis (i.e., changing from AIA to pre-AIA ) for the rejection will not be considered a new ground of rejection if the prior art relied upon, and the rationale supporting the rejection, would be the same under either status. Continued Examination Under 37 CFR 1.114 A request for continued examination under 37 CFR 1.114, including the fee set forth in 37 CFR 1.17(e), was filed in this application after final rejection. Since this application is eligible for continued examination under 37 CFR 1.114, and the fee set forth in 37 CFR 1.17(e) has been timely paid, the finality of the previous Office action has been withdrawn pursuant to 37 CFR 1.114. Applicant's submission filed on 9/23/25 has been entered. Notice of Amendment In response to the amendment(s) filed on 9/23/25, amended claim(s) 1 is/are acknowledged. The following new and/or reiterated ground(s) of rejection is/are set forth: Claim Rejections - 35 USC § 103 The following is a quotation of pre-AIA 35 U.S.C. 103(a) which forms the basis for all obviousness rejections set forth in this Office action: (a) A patent may not be obtained though the invention is not identically disclosed or described as set forth in section 102, if the differences between the subject matter sought to be patented and the prior art are such that the subject matter as a whole would have been obvious at the time the invention was made to a person having ordinary skill in the art to which said subject matter pertains. Patentability shall not be negated by the manner in which the invention was made. This application currently names joint inventors. In considering patentability of the claims under pre-AIA 35 U.S.C. 103(a), the examiner presumes that the subject matter of the various claims was commonly owned at the time any inventions covered therein were made absent any evidence to the contrary. Applicant is advised of the obligation under 37 CFR 1.56 to point out the inventor and invention dates of each claim that was not commonly owned at the time a later invention was made in order for the examiner to consider the applicability of pre-AIA 35 U.S.C. 103(c) and potential pre-AIA 35 U.S.C. 102(e), (f) or (g) prior art under pre-AIA 35 U.S.C. 103(a). Claim(s) 1-2, 6, 8-15, and 20 is/are rejected under pre-AIA 35 U.S.C. 103(a) as being unpatentable over U.S. Patent Application Publication No. 2009/0088650 to Corl in view of U.S. Patent Application Publication No. 2011/0213220 to Samuelsson et al. (hereinafter “Samuelsson”) and U.S. Patent Application Publication No. 2004/0010303 to Bolea et al. (hereinafter “Bolea”). For claim 1, Corl discloses a system (Abstract), comprising: a sensing guidewire (“sensing guidewire,” para [0029]), comprising: a flexible elongate member (“flexible elongate member,” para [0001]) configured to (Examiner’s Note: functional language, i.e., capable of) be positioned within a blood vessel of a patient (para [0001]), the flexible elongate member comprising a central longitudinal axis (central longitudinal axis of “flexible elongate member,” para [0001]), a proximal portion (proximal portion of “flexible elongate member,” para [0001]), and a distal portion (distal portion of “flexible elongate member,” para [0001]); a core wire (“core wire,” para [0033]) disposed within the flexible elongate member (para [0033]) (also see Fig. 3b), wherein the core wire comprises a distal surface disposed at a distal end of the core wire (unlabeled, but as can be seen in Figs. 9-10); a plurality of electrical wires (105) (Fig. 3b) (para [0043]) (also see 218 in Figs. 9) extending proximate to the core wire (as can be seen in Fig. 3b) (also see para [0033]-[0034] that discloses that the core wire extends proximally to 58 and that the lines and cable extend beyond 58 to 50, as can be seen in Fig. 2) and in a direction of the central longitudinal axis along a length of the flexible elongate member from the proximal portion to the distal portion (as can be seen in Figs. 3b and 9); and a sensor assembly (“sensor assembly,” para [0001]) disposed at the distal portion of the flexible elongate member (para [0001]), wherein the sensor assembly comprises: a substrate (100/200) (Figs. 3a-b/9) (para [0042]/[0051]) comprising: a semiconductor material (para [0023] and [0058]-[0060]) comprising a length defined along the central longitudinal axis (as can be seen in Figs. 3a-b), a width extending perpendicular to the central longitudinal axis (as can be seen in Figs. 3a-b), a distal surface disposed at a distal end of the length of the semiconductor material such that the distal surface of the semiconductor material is forward-facing (unlabeled, forward-facing distal surface of 200 shown in Fig. 9), and a proximal surface disposed at a proximal end of the length of the semiconductor material (unlabeled, but as can be seen in Figs. 9-10); a plurality of electrodes (108) (Fig. 3a) (para [0043]) formed using semiconductor manufacturing (para [0027]) (also see para [0023] and [0058]-[0060]), wherein the plurality of electrodes is part of the substrate such that the plurality of electrodes extends through the semiconductor material is a direction of the length of the semiconductor material and in the direction of the central longitudinal axis (as can be seen in Figs. 3a and 4-5); and a physiological sensor (202) (Fig. 9) para [0052]) disposed on the distal surface of the semiconductor material such that the physiological sensor is forward-facing (as can be seen in Fig. 9), wherein the physiological sensor comprises at least one of a pressure sensor or a flow sensor (para [0056]), wherein the physiological sensor is in communication with: the plurality of electrodes (para [0038]) (also see para [0043]); and the plurality of electrical wires via the plurality of electrodes (para [0038]) (also see para [0043]), wherein the plurality of electrical wires is coupled to the plurality of electrodes (para [0043]) between the distal surface of the core wire and the proximal surface of the semiconductor material (as can be seen in Figs. 3a-b) (Examiner’s Note: 106 is part of 100 as evidenced by para [0042] and para [0033] state that the “core wire extends from the distal tip of the guidewire to the proximal (connector) end of the guidewire 56”). Corl does not expressly disclose wherein the proximal surface of the semiconductor material abuts the distal surface of the core wire. However, Samuelsson teaches wherein a proximal surface of a semiconductor material (see “sensor chip” in Figs. 7-8) abuts the distal surface of a core wire (see “core wire” in Figs. 7-8). It would have been obvious to a skilled artisan to modify Corl wherein the proximal surface of the semiconductor material abuts the distal surface of the core wire, in view of the teachings of Samuelsson, as another medium by which the signals from the sensor can be transferred (see Abstract of Samuelsson). Corl and Samuelsson do not expressly disclose wherein the plurality of electrodes is fully encapsulated by the substrate. However, Bolea teaches wherein a plurality of electrodes is fully encapsulated by a substrate (as can be seen in Figs. 8-11) (also see para [0093]). It would have been obvious to a skilled artisan to modify Corl wherein the plurality of electrodes is fully encapsulated by the substrate, in view of the teachings of Bolea, for the obvious advantage of protecting the electrodes on all sides. For claim 2, Corl further discloses wherein the sensor assembly further comprises at least one of an application specific integrated circuit (ASIC), a signal conditioning circuit, an RF communication module, or a memory module (para [0031]-[0034]). For claim 6, Corl further discloses wherein the plurality of electrodes extend in the direction of the length from the distal surface (para [0054]) to the proximal surface of the semiconductor material (as can be seen in Figs. 3a and 4-5). For claim 8, Corl further discloses wherein the semiconductor material comprises at least one of silicon, germanium, a silicon-germanium alloy, silica, quartz, sapphire, a ceramic material, or a plastic material (para [0004] and [0059]). For claim 9, Corl further discloses wherein the substrate is bonded to at least one of the flexible elongate member or the core wire using an adhesive (para [0048]). For claim 10, Corl further discloses wherein the flexible elongate member comprises a hole configured to expose the physiological sensor to blood within the blood vessel (101) (Fig. 3b) (para [0045]). For claim 11, Corl further discloses a control console (52) in communication with the sensing guidewire (as can be seen in Fig. 2). For claim 12, Corl further discloses an interface device (50) (Fig. 2) communicatively disposed between the control console and the sensing guidewire (as can be seen in Fig. 2), wherein the interface device is configured to provide power to the physiological sensor and process a signal from the physiological sensor (para [0035]). For claim 13, Corl further discloses wherein the interface device comprises an analog to digital converting circuit configured to provide a digital signal to the control console (para [0032] and [0038]). For claim 14, Corl further discloses wherein the control console is configured to output a visual representation of data obtained by the physiological sensor (as can be seen in Fig. 2). For claim 15, Corl further discloses wherein the physiological sensor comprises a micromechanical system (MEMS) sensor (para [0007]). For claim 20, Corl further discloses wherein the substrate further comprise a plurality of conductors (204a, 204b, 204c) in communication with the plurality of electrodes (as can be seen in Figs. 6-7) (para [0052]), wherein the plurality of conductors form part of the substrate such that the plurality of conductors extend along the distal surface of the semiconductor material in a direction of the width of the semiconductor material (as can be seen in Figs. 6-7), and wherein the physiological sensor is in communication with the plurality of electrical wires via the plurality of electrodes and the plurality of conductors (para [0052]). Claim(s) 3 is/are rejected under pre-AIA 35 U.S.C. 103(a) as being unpatentable over Corl in view of Samuelsson and Bolea, and further in view of U.S. Patent Application Publication No. 2011/0072659 to Swanson et al. (hereinafter “Swanson”). For claim 3, Corl, Samuelsson, and Bolea do not expressly disclose wherein the substrate comprises an elongated cylinder. However, Swanson teaches wherein the substrate comprises an elongated cylinder (Abstract) (Fig. 3) (para [0009]). It would have been obvious to a skilled artisan to modify Corl wherein the substrate comprises an elongated cylinder, in view of the teachings of Swanson, because such a combination could be achieved by known methods (such as the semiconductor manufacturing methods disclosed in Corl) and would have each element perform the same together as they do separately that the combination would lead to the predictable purpose of intravascular use, which is what Corl wants to do (see Abstract of Corl). Claim(s) 16 is/are rejected under pre-AIA 35 U.S.C. 103(a) as being unpatentable over Corl in view of Samuelsson and Bolea, and further in view of U.S. Patent Application Publication No. 2013/0324863 to Yu et al. (hereinafter “Yu”). For claim 16, Corl, Samuelsson, and Bolea do not expressly disclose wherein the physiological sensor comprises an ultrasound transducer. However, Yu teaches wherein the physiological sensor comprises an ultrasound transducer (para [0041]). It would have been obvious to a skilled artisan to modify Corl wherein the physiological sensor comprises an ultrasound transducer, in view of the teachings of Yu, because such a modification would be the simple substitution of one sensor type for another sensor type that would lead to the predictable result of sensing properties of the patient’s blood. Claim(s) 17 is/are rejected under pre-AIA 35 U.S.C. 103(a) as being unpatentable over Corl in view of Samuelsson and Bolea, and further in view of U.S. Patent Application Publication No. 2011/034912 to de Graff et al. (hereinafter “de Graff”). For claim 17, Corl, Samuelsson, and Bolea do not expressly disclose wherein the physiological sensor is flip-chip bonded to the distal surface of the substrate. However, de Graff teaches wherein the physiological sensor is flip-chip bonded to the distal surface of the substrate (para [0099]). It would have been obvious to a skilled artisan to modify Corl wherein the physiological sensor is flip-chip bonded to the distal surface of the substrate, in view of the teachings of de Graff, because such a modification would be the simple substitution of the medium by which to bond the sensor to the surface of the substrate. Response to Arguments Applicant’s arguments have been considered but are moot because the arguments do not address the new grounds of rejection necessitated by Applicant’s amendments presented in the response filed 9/23/25. Conclusion Any inquiry concerning this communication or earlier communications from the examiner should be directed to DANIEL LEE CERIONI whose telephone number is (313) 446-4818. The examiner can normally be reached M - F 8:00 AM - 5:00 PM PT. Examiner interviews are available via telephone, in-person, and video conferencing using a USPTO supplied web-based collaboration tool. To schedule an interview, applicant is encouraged to use the USPTO Automated Interview Request (AIR) at http://www.uspto.gov/interviewpractice. If attempts to reach the examiner by telephone are unsuccessful, the examiner’s supervisor, Jennifer Robertson can be reached on (571) 272-5001. The fax phone number for the organization where this application or proceeding is assigned is 571-273-8300. Information regarding the status of published or unpublished applications may be obtained from Patent Center. Unpublished application information in Patent Center is available to registered users. To file and manage patent submissions in Patent Center, visit: https://patentcenter.uspto.gov. Visit https://www.uspto.gov/patents/apply/patent-center for more information about Patent Center and https://www.uspto.gov/patents/docx for information about filing in DOCX format. For additional questions, contact the Electronic Business Center (EBC) at 866-217-9197 (toll-free). If you would like assistance from a USPTO Customer Service Representative, call 800-786-9199 (IN USA OR CANADA) or 571-272-1000. /DANIEL L CERIONI/Primary Examiner, Art Unit 3791
Read full office action

Prosecution Timeline

Jan 03, 2019
Application Filed
Jul 17, 2021
Non-Final Rejection — §103
Oct 19, 2021
Response Filed
Dec 28, 2021
Final Rejection — §103
Mar 07, 2022
Response after Non-Final Action
Apr 01, 2022
Examiner Interview (Telephonic)
Apr 02, 2022
Response after Non-Final Action
Apr 06, 2022
Request for Continued Examination
Apr 08, 2022
Response after Non-Final Action
Aug 01, 2022
Non-Final Rejection — §103
Nov 07, 2022
Response Filed
Mar 06, 2023
Examiner Interview (Telephonic)
Mar 07, 2023
Final Rejection — §103
May 15, 2023
Response after Non-Final Action
Jul 19, 2023
Examiner Interview (Telephonic)
Jul 19, 2023
Response after Non-Final Action
Jul 25, 2023
Request for Continued Examination
Jul 29, 2023
Response after Non-Final Action
Aug 20, 2023
Non-Final Rejection — §103
Nov 17, 2023
Response Filed
May 02, 2024
Non-Final Rejection — §103
Aug 07, 2024
Response Filed
Aug 08, 2024
Final Rejection — §103
Oct 15, 2024
Response after Non-Final Action
Oct 21, 2024
Response after Non-Final Action
Nov 06, 2024
Request for Continued Examination
Nov 07, 2024
Response after Non-Final Action
Nov 12, 2024
Examiner Interview Summary
Nov 12, 2024
Applicant Interview (Telephonic)
Mar 18, 2025
Non-Final Rejection — §103
Jun 17, 2025
Response Filed
Jun 23, 2025
Final Rejection — §103
Aug 25, 2025
Response after Non-Final Action
Sep 23, 2025
Request for Continued Examination
Sep 23, 2025
Examiner Interview Summary
Sep 23, 2025
Applicant Interview (Telephonic)
Oct 01, 2025
Response after Non-Final Action
Jan 08, 2026
Non-Final Rejection — §103 (current)

Precedent Cases

Applications granted by this same examiner with similar technology

Patent 12599338
DEFLECTABLE ELONGATED GUIDEWIRE ASSEMBLY
2y 5m to grant Granted Apr 14, 2026
Patent 12601641
Temperature Estimation Method, Temperature Estimation Program and Temperature Estimation Device
2y 5m to grant Granted Apr 14, 2026
Patent 12594062
FLUID COLLECTION ASSEMBLIES INCLUDING AN EXTENSION
2y 5m to grant Granted Apr 07, 2026
Patent 12588949
LASER ABLATION WITH ELECTROMAGNETIC ENERGY FEEDBACK
2y 5m to grant Granted Mar 31, 2026
Patent 12582344
WIRELESS STIMULATION PROBE DEVICE FOR WIRELESS NERVE INTEGRITY MONITORING SYSTEMS
2y 5m to grant Granted Mar 24, 2026
Study what changed to get past this examiner. Based on 5 most recent grants.

AI Strategy Recommendation

Get an AI-powered prosecution strategy using examiner precedents, rejection analysis, and claim mapping.
Powered by AI — typically takes 5-10 seconds

Prosecution Projections

10-11
Expected OA Rounds
65%
Grant Probability
93%
With Interview (+28.6%)
3y 9m
Median Time to Grant
High
PTA Risk
Based on 749 resolved cases by this examiner. Grant probability derived from career allow rate.

Sign in with your work email

Enter your email to receive a magic link. No password needed.

Personal email addresses (Gmail, Yahoo, etc.) are not accepted.

Free tier: 3 strategy analyses per month